IN2015DN01900A - - Google Patents
Info
- Publication number
- IN2015DN01900A IN2015DN01900A IN1900DEN2015A IN2015DN01900A IN 2015DN01900 A IN2015DN01900 A IN 2015DN01900A IN 1900DEN2015 A IN1900DEN2015 A IN 1900DEN2015A IN 2015DN01900 A IN2015DN01900 A IN 2015DN01900A
- Authority
- IN
- India
- Prior art keywords
- disorders
- formula
- tautomers
- prodrugs
- variables
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Abstract
The present invention relates to compounds of the formula I the N oxides tautomers the prodrugs and the pharmaceutically acceptable salts thereof. where in formula I the variables X Y Q Q have the following meanings: X is C R or N; Q is S or O and Q is C R or N and Q is connected to X via a double bond while Q is connected to X via a single bond; or Q is S or O and Q is C R or N and Q is connected to X via a double bond while Q is connected to X via a single bond; Y is C R or N; where in formula I the variables R R R R and R are as defined in the claims The compounds of the formula I the N oxides tautomers the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261702005P | 2012-09-17 | 2012-09-17 | |
US201261702371P | 2012-09-18 | 2012-09-18 | |
PCT/EP2013/069173 WO2014041175A1 (en) | 2012-09-17 | 2013-09-16 | Novel inhibitor compounds of phosphodiesterase type 10a |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN01900A true IN2015DN01900A (en) | 2015-08-07 |
Family
ID=49226152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1900DEN2015 IN2015DN01900A (en) | 2012-09-17 | 2013-09-16 |
Country Status (19)
Country | Link |
---|---|
US (1) | US9388180B2 (en) |
EP (1) | EP2895489B1 (en) |
JP (1) | JP2015528484A (en) |
KR (1) | KR20150056844A (en) |
CN (1) | CN105102461A (en) |
AR (1) | AR092595A1 (en) |
AU (1) | AU2013314244A1 (en) |
BR (1) | BR112015005935A2 (en) |
CA (1) | CA2883910A1 (en) |
HK (1) | HK1206728A1 (en) |
IL (1) | IL237626A0 (en) |
IN (1) | IN2015DN01900A (en) |
MX (1) | MX2015003419A (en) |
RU (1) | RU2015114331A (en) |
SG (1) | SG11201502074YA (en) |
TW (1) | TW201418264A (en) |
UY (1) | UY35036A (en) |
WO (1) | WO2014041175A1 (en) |
ZA (1) | ZA201501458B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015004427A2 (en) | 2012-10-26 | 2017-07-04 | Hoffmann La Roche | compounds, methods for treating an inflammatory condition, rheumatoid arthritis, asthma, an immune disorder and an immune disorder and pharmaceutical composition |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
US11066465B2 (en) | 2015-12-30 | 2021-07-20 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
CN111592495A (en) * | 2020-07-06 | 2020-08-28 | 上海启讯医药科技有限公司 | Preparation method of 2-n-butyl-4-chloro-5-formylimidazole |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
US7057042B2 (en) * | 2002-05-29 | 2006-06-06 | Abbott Laboratories | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction |
US20070032404A1 (en) | 2003-07-31 | 2007-02-08 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
CA2568929A1 (en) | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
CA2578996A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
AP2007003923A0 (en) * | 2004-09-30 | 2007-02-28 | Tibotec Pharm Ltd | Hcv inhibiting bi-cyclic pyrimidines |
MX2008002207A (en) | 2005-08-16 | 2008-03-27 | Memory Pharm Corp | Phosphodiesterase 10 inhibitors. |
NL2000397C2 (en) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclic heteroaryl compounds as PDE10 inhibitors. |
WO2007082546A1 (en) | 2006-01-20 | 2007-07-26 | H. Lundbeck A/S | Use of tofisopam as a pde10a inhibitor |
BRPI0707223A2 (en) | 2006-01-27 | 2011-04-26 | Pfizer Prod Inc | aminophthalazine derivative compounds |
WO2007098214A1 (en) | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
CA2643963A1 (en) | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
CA2641670A1 (en) | 2006-02-23 | 2007-08-30 | Pfizer Products Inc. | Substituted quinazolines as pde10 inhibitors |
CA2643044A1 (en) | 2006-02-28 | 2007-09-07 | Amgen Inc. | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors |
US20070265258A1 (en) | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
MX2008011257A (en) | 2006-03-08 | 2008-09-25 | Amgen Inc | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors. |
TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
WO2008001182A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
SI2057153T1 (en) | 2006-07-10 | 2012-12-31 | H. Lundbeck A/S | (3-aryl-piperazin-1-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline |
WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
WO2009025823A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
WO2009025839A2 (en) | 2007-08-22 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
WO2009029214A1 (en) | 2007-08-23 | 2009-03-05 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
TW200918519A (en) | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
CN101918408A (en) * | 2007-11-30 | 2010-12-15 | 惠氏有限责任公司 | Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10 |
US20090143361A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
CA2706986A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
WO2009068246A2 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of treating obesity and metabolic disorders |
RU2545023C9 (en) | 2008-06-10 | 2016-06-20 | Эббви Инк. | Tricyclic compounds, pharmaceutical composition containing them and using them for treating immunological and oncological compounds |
US20100120763A1 (en) * | 2008-11-07 | 2010-05-13 | Wyeth | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
WO2011008597A1 (en) | 2009-07-14 | 2011-01-20 | Schering Corporation | Dihydroimidazoisoquinoline derivatives useful as pde10 inhibitors |
US8361962B2 (en) | 2009-07-27 | 2013-01-29 | Roche Palo Alto Llc | Tricyclic inhibitors of JAK |
-
2013
- 2013-09-16 CA CA2883910A patent/CA2883910A1/en not_active Abandoned
- 2013-09-16 SG SG11201502074YA patent/SG11201502074YA/en unknown
- 2013-09-16 BR BR112015005935A patent/BR112015005935A2/en not_active IP Right Cessation
- 2013-09-16 JP JP2015531593A patent/JP2015528484A/en not_active Withdrawn
- 2013-09-16 WO PCT/EP2013/069173 patent/WO2014041175A1/en active Application Filing
- 2013-09-16 EP EP13765695.5A patent/EP2895489B1/en not_active Not-in-force
- 2013-09-16 MX MX2015003419A patent/MX2015003419A/en unknown
- 2013-09-16 AU AU2013314244A patent/AU2013314244A1/en not_active Abandoned
- 2013-09-16 CN CN201380048224.3A patent/CN105102461A/en active Pending
- 2013-09-16 RU RU2015114331A patent/RU2015114331A/en not_active Application Discontinuation
- 2013-09-16 IN IN1900DEN2015 patent/IN2015DN01900A/en unknown
- 2013-09-16 KR KR1020157009897A patent/KR20150056844A/en not_active Application Discontinuation
- 2013-09-17 AR ARP130103326A patent/AR092595A1/en unknown
- 2013-09-17 US US14/029,142 patent/US9388180B2/en active Active
- 2013-09-17 UY UY0001035036A patent/UY35036A/en not_active Application Discontinuation
- 2013-09-17 TW TW102133710A patent/TW201418264A/en unknown
-
2015
- 2015-03-03 ZA ZA2015/01458A patent/ZA201501458B/en unknown
- 2015-03-09 IL IL237626A patent/IL237626A0/en unknown
- 2015-07-28 HK HK15107215.7A patent/HK1206728A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20140107126A1 (en) | 2014-04-17 |
KR20150056844A (en) | 2015-05-27 |
AU2013314244A1 (en) | 2015-03-12 |
ZA201501458B (en) | 2018-11-28 |
EP2895489A1 (en) | 2015-07-22 |
TW201418264A (en) | 2014-05-16 |
MX2015003419A (en) | 2015-09-23 |
WO2014041175A1 (en) | 2014-03-20 |
AU2013314244A8 (en) | 2015-04-30 |
EP2895489B1 (en) | 2017-10-18 |
AR092595A1 (en) | 2015-04-29 |
BR112015005935A2 (en) | 2017-07-04 |
IL237626A0 (en) | 2015-04-30 |
CN105102461A (en) | 2015-11-25 |
SG11201502074YA (en) | 2015-05-28 |
JP2015528484A (en) | 2015-09-28 |
UY35036A (en) | 2014-03-31 |
RU2015114331A (en) | 2016-11-10 |
US9388180B2 (en) | 2016-07-12 |
HK1206728A1 (en) | 2016-01-15 |
CA2883910A1 (en) | 2014-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015012008A (en) | Novel inhibitor compounds of phosphodiesterase type 10a. | |
AU2012277802A8 (en) | Novel inhibitor compounds of phosphodiesterase type 10A | |
TN2015000368A1 (en) | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | |
MD20160078A2 (en) | Syk inhibitors | |
PH12015500488A1 (en) | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
TN2013000285A1 (en) | Novel heterocyclic derivatives and their use in the treatment of neurological disorders | |
MX2012012952A (en) | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds. | |
GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
PH12015501962A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a | |
MX2012001070A (en) | Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders. | |
GEP201706748B (en) | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors | |
MX2013011908A (en) | Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors. | |
CR20200286A (en) | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | |
MX2013008056A (en) | 1,4-oxazepines as bace1 and/or bace2 inhibitors. | |
MY182559A (en) | Process for the preparation of a pde4 inhibitor | |
BR112015009649A2 (en) | triazole compound | |
WO2011107608A8 (en) | Heterocyclic amides as rock inhibitors | |
PH12014502541A1 (en) | 5-amino [1,4] thiazines as bace 1 inhibitors | |
MX2013008340A (en) | Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer. | |
IN2015DN01900A (en) | ||
MX2013002208A (en) | Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes. | |
MX2013003202A (en) | Oxadiazole inhibitors of leukotriene production. | |
MX2015006539A (en) | Novel inhibitor compounds of phosphodiesterase type 10a. | |
MX2013011561A (en) | Benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetes. | |
PH12015500348A1 (en) | Inhibitor compounds of phosphodiesterase type 10a |